RXRX Today - Aug 10: Analysts Trim Revenue Forecasts

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

RXRX Today - Aug 10: Analysts Trim Revenue Forecasts

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly investor, and I'm here to break down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day, down about 2.5%.

So, what happened? RXRX started off with some mixed vibes after their Q2 results came out. They reported a narrower net loss, which usually gets people a little excited, right? But then analysts came in and dropped their revenue forecasts by a whopping 19%. Yeah, that one stung. People were quick to hit the sell button, and it showed in the stock price.

Now, let’s unpack why this all went down. The earnings call highlighted that while they’re making progress, folks are worried about those revenue cuts. Investors want to see growth, and when the numbers aren’t looking promising, it’s a hard pill to swallow. Plus, with AbCellera’s shares surging, some investors might be looking for greener pastures elsewhere. It’s tough out there!

Looking ahead, one thing to keep in mind is that Recursion is still in the game. They've got more trials and developments lined up, so while today's news was a bummer, there’s still potential on the horizon.

Alright, that’s the scoop on RXRX today! Remember, this is just me sharing info, not financial advice. Keep it chill and happy investing!

まだレビューはありません